JNK

亜型選択性的な製品

JNK製品

  • All (42)
  • JNK阻害剤 (31)
  • JNK活性剤(10)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S1460 SP600125 SP600125(Nsc75890)は、JNK1、JNK2、JNK3に対する広範なJNK阻害剤であり、細胞フリーアッセイでのIC50はそれぞれ40nM、40nM、90nMです。MKK4に対して10倍、MKK3、MKK6、PKB、PKCαに対して25倍、ERK2、p38、Chk1、EGFRなどに対して100倍高い選択性を示します。SP600125は、Aurora kinase AFLT3TRKAを含むserine/threonine kinasesの広範な阻害剤でもあり、IC50はそれぞれ60nM、90nM、70nMです。SP600125はautophagyを阻害し、apoptosisを活性化します。
Nat Commun, 2025, 16(1):7156
Adv Sci (Weinh), 2025, 12(28):e2502634
Adv Sci (Weinh), 2025, 12(36):e00028
SP600125-S1460W01210140905.gif
S1574 Doramapimod (BIRB 796) Doramapimod (BIRB 796) は、細胞を含まないアッセイでp38α/β/γ/δに対して38 nM、65 nM、200 nM、520 nMのIC50を持つpan-p38 MAPK阻害剤であり、THP-1細胞では0.1 nMのKdでp38αに結合し、JNK2と比較して330倍高い選択性を示します。c-RAF、Fyn、Lckに対しては弱い阻害作用を示し、ERK-1、SYK、IKK2に対しては有意な阻害作用を示しません。
Nat Cancer, 2025, 6(2):259-277
Nat Commun, 2025, 16(1):3319
Nat Commun, 2025, 16(1):1834
BIRB796-S1574W0220141114.gif
S1950 Metformin Hydrochloride Metformin Hydrochloride(1,1-ジメチルビグアナイドHCl)は、主に肝臓によるグルコース産生(肝糖新生)を抑制することにより、肝細胞の高血糖を低下させます。Metformin Hydrochlorideは単核細胞のmitophagyを促進します。Metformin Hydrochlorideは、JNK/p38 MAPK経路とGADD153を活性化することにより、肺癌細胞のapoptosisを誘導します。
Cell Biosci, 2025, 15(1):156
mBio, 2025, e0063425
Placenta, 2025, 165:50-61
Metformin-S195007W0220150831.gif
S4901 JNK-IN-8 JNK-IN-8 (JNK Inhibitor XVI) は、JNK1、JNK2、JNK3に対する初の不可逆的JNK阻害剤であり、IC50はそれぞれ4.7 nM、18.7 nM、1 nMです。A375細胞株において、MNK2、Fmsに対して10倍以上の選択性を示し、c-Kit、Met、PDGFRβに対しては阻害作用を示しません。
Cancer Cell, 2025, S1535-6108(25)00271-5
Cell Res, 2025, 10.1038/s41422-025-01085-9
Nat Commun, 2025, 16(1):4884
JNK-IN-8-S4901Z0120140901.gif
S7409 Anisomycin (Flagecidin) Anisomycin (Flagecidin, Wuningmeisu C) is a bacterial antibiotic isolated from Streptomyces griseolus, which inhibits protein synthesis, and also act as a JNK activator. Anisomycin upregulates autophagy and increases apoptosis.
J Exp Med, 2025, 222(6)e20240272
Cell Rep Med, 2025, 6(2):101927
Theranostics, 2025, 15(10):4398-4415
Anisomycin-S740901W0220170720.gif
S1396 Resveratrol (trans-Resveratrol) Resveratrolは、シクロオキシゲナーゼ(例:COX、IC50=1.1 μM)、リポキシゲナーゼ(LOX、IC50=2.7 μM)、キナーゼ、Sirtuin、その他のタンパク質を含む幅広い標的を持っています。抗がん作用、抗炎症作用、血糖降下作用、その他心血管に良い効果があります。Resveratrolはmitophagy/autophagyおよびオートファジー依存性apoptosisを誘導します。
Aging Cell, 2025, e70075
Biomed Pharmacother, 2025, 190:118393
Breast Cancer Res, 2025, 27(1):186
Resveratrol-S139601W0120130129.gif
S5958 Metformin (1,1-Dimethylbiguanide) Metformin (1,1-Dimethylbiguanide), a widely used drug for treatment of type 2 diabetes, activates AMP-activated protein kinase (AMPK) in hepatocytes. Metformin promotes mitophagy in mononuclear cells. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153.
Signal Transduct Target Ther, 2025, 10(1):271
Theranostics, 2025, 15(17):9029-9046
Int J Biol Sci, 2025, 21(9):4231-4251
S2271 Berberine chloride Berberine chlorideは、イソキノリンアルカロイド群の第四級アンモニウム塩です。Berberine chlorideは、caspase 3caspase 8を活性化し、poly ADP-ribose polymerase (PARP)の切断とcytochrome cの放出を促進します。Berberine chlorideは、c-IAP1Bcl-2、およびBcl-XLの発現を減少させます。Berberine chlorideは、JNKp38 MAPKの持続的なリン酸化およびROSの生成を伴うapoptosisを誘導します。Berberine chlorideは、デュアルtopoisomerase IおよびII阻害剤です。Berberine chlorideは、潜在的なautophagyモジュレーターでもあります。
J Cardiovasc Dev Dis, 2025, 12(7)278
Adv Healthc Mater, 2023, e2300591.
Transl Oncol, 2023, 35:101712
S7508 JNK Inhibitor IX JNK Inhibitor IX (TCS JNK 5a) は、JNK2 および JNK3 に対する pIC50 がそれぞれ 6.5 および 6.7 の、選択的かつ強力な JNK 阻害剤です。
Res Sq, 2025, rs.3.rs-6150649
Sci Adv, 2024, 10(50):eadq4274
Cell Mol Immunol, 2023, 20(8):908-923
JNK-Inhibitor-IX-S750801Z0420161125.gif
S8490 Tanzisertib Hydrochloride (CC-930) Tanzisertib HCl(CC-930, JNK-930, JNKI-1) is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively.
Nature, 2025, 644(8076):516-526
J Neuroinflammation, 2025, 22(1):32
Cancer Cell, 2024, 42(4):535-551.e8
S7794 JNK Inhibitor VIII JNK Inhibitor VIII (TCS JNK 6o) is an inhibitor of c-Jun N-terminal kinases with IC50 of 45 nM and 160 nM for JNK-1 and JNK-2, respectively. JNK Inhibitor VIII (TCS JNK 6o) inihibits JNK-1, JNK-2, and JNK-3 with Ki of 2 nM, 4 nM and 52 nM, respectively.
Cell, 2024, 187(14):3652-3670.e40
Cell Death Discov, 2022, 8(1):113
Molecules, 2021, 26(8)2141
S3901 Astragaloside IV Astragaloside IV (AST-IV, AS-IV) is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. It has various effect on the cardiovascular, immune, digestive, and nervous systems. AS-IV suppresses activation of p-Akt, p-mTOR, p-NF-κB and p-Erk1/2.
Cell Transplant, 2023, 32:9636897231198167
Cell Cycle, 2022, 1-14
Naunyn Schmiedebergs Arch Pharmacol, 2020, 10.1007/s00210-020-02022-w
S3292 (3R,8S)-Falcarindiol Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules.
Antioxidants (Basel), 2024, 13(12)1533
Front Cell Infect Microbiol, 2023, 13:1128000
Front Pharmacol, 2021, 12:656697
S9114 Polyphyllin I Polyphyllin I, a small molecular monomer extracted from Rhizoma of Paris polyphyllin, is used in the treatment of infectious disease and cancer. Polyphyllin I inhibits proliferation and induces apoptotic cell death in U251 cells. Polyphyllin I is an activator of the JNK signaling pathway with a potential anti-glioma effect.
Discov Oncol, 2025, 16(1):941
Mol Med, 2024, 30(1):59
Oxid Med Cell Longev, 2022, 2022:4031008
S8867 Bentamapimod (AS602801) Bentamapimod (AS602801) is a novel, orally active JNK inhibitor with IC50 values of 80 nM, 90 nM and 230 nM for JNK1, JNK2 and JNK3 respectively.
Front Oncol, 2022, 12:1006131
Nat Biomed Eng, 2018, 2(8):578-588
S7637 DTP3 DTP3 is a selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor and is able to restore MKK7/JNK activation. DTP3 inhibits cancer-selective NF-κB survival pathway.
Life Sci Alliance, 2024, 7(8)e202302555
MedComm (2020), 2023, 4(3):e269
S8201 BI-78D3 BI-78D3 is a competitive JNK inhibitor with IC50 of 280nM that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K.
Neoplasia, 2021, 23(7):718-730
Cell Discov, 2019, 5:2
S3940 3'-Hydroxypterostilbene 3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies.
Int J Mol Sci, 2024, 25(18)9990
S0781 IQ 3 IQ 3 is a specific c-Jun N-terminal kinase (JNK) inhibitor with Kd of 66 nM, 240 nM and 290 nM for JNK3, JNK1 and JNK2, respectively. IQ 3 inhibits LPS-induced NF-κB/AP1 transcriptional activity in THP1-Blue cells with IC50 of 1.4 μM. IQ 3 also inhibits TNF-α and IL-6 production in vitro.
Int J Biol Sci, 2024, 20(6):2323-2338
E1391 SP 600125, negative control SP 600125, negative control (JNK inhibitor II, negative control) is a methylated analog of SP 600125 and inhibits JNK2 and JNK3 with IC50 of 18 µM and 24 µM, respectively.
Cell Death Dis, 2023, 14(8):537
S6730 CC-401 Hydrochloride CC-401 is a potent inhibitor of JNK with at least 40-fold selectivity against other related kinases.
Insect Biochem Mol Biol, 2016, 73:55-61
S3811 Ginsenoside Re Ginsenoside Re (Ginsenoside B2, Panaxoside Re, Sanchinoside Re, Chikusetsusaponin Ivc), an extract from Panax notoginseng, is a major ginsenoside in ginseng and belongs to 20(S)-protopanaxatriol group. It has diverse in vitro and in vivo effects, including vasorelaxant, antioxidant, antihyperlipidemic, and angiogenic actions. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.
J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S1321 Urolithin B Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα. Urolithin B suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass.
PLoS Pathog, 2025, 21(8):e1013401
S6740 DB07268 DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM and exhibits at least 70- to 90-fold greater potency against JNK1 than CHK1, CK2, and PLK.
S4643 KB-R7943 mesylate KB-R7943 mesylate is a widely used inhibitor of the reverse Na+/Ca2+ exchanger (NCX(rev)) with IC50 of 5.7 μM. KB-R7943 mesylate promotes prostate cancer cell death by activating the JNK pathway and blocking autophagic flux.
E8271New Sanguinarine citrate Sanguinarine (gluconate) is a benzophenanthridine alkaloid derived from the root of Sanguinaria canadensis. It activates reactive oxygen species (ROS), c-Jun N-terminal kinase (JNK), and nuclear factor-kappaB (NF-κB) signaling pathways to induce apoptosis in head and neck tumor cells and animal models. It also exhibits potent anti-bacterial and anti-inflammatory activities.
E2653 JNK-IN-7 JNK-IN-7 is a strong  JNK inhibitor with IC50 of 1.5, 2 and 0.7 nM for JNK1, JNK2 and JNK3, which inhibits phosphorylation of c-Jun, direct substrate of JNK kinase.
S3242 Loureirin B Loureirin B (LB, LrB), a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of PAI-1 with IC50 of 26.10 μM. Loureirin B downregulates p-ERK and p-JNK in TGF-β1-stimulated fibroblasts. Loureirin B promotes insulin secretion mainly through increasing Pdx-1, MafA, intracellular ATP level, inhibiting the KATP current, influx of Ca2+ to the intracellular.
S0949 Cucurbitacin IIb Cucurbitacin IIb (CuIIb, Dihydrocucurbitacin F, 25-deacetyl hemslecin A) inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB, blocks nuclear translocation of NF-κB and decreases mRNA levels of IκBα and TNF-α. Cucurbitacin IIb exhibits anti-inflammatory activity and induces apoptosis. Cucurbitacin IIb is isolated from Hemsleya amabilis.
S4884 Trans-Zeatin Trans-Zeatina ((E)-Zeatin) is the member of the plant growth hormone family known as cytokinins, which regulate cell division, development, and nutrient processing. Trans-Zeatin inhibits UVB-induced MMP-1 expression, c-Jun activation and phosphorylation of ERK, JNK and p38 MAP kinases (MAPKs) dose-dependently.
S9614 CC-90001 CC-90001 is an orally administered inhibitor of c-Jun N-terminal kinase (JNK) with bias for JNK1 over JNK2. It exhibits antifibrotic efficacy and can be used for the research of idiopathic pulmonary fibrosis.
S9698 Ezatiostat Ezatiostat, a tripeptide analog of glutathione, is a peptidomimetic inhibitor of Glutathione S-transferase P1-1 (GSTP1-1). Ezatiostat activates c-Jun NH2 terminal kinase (JNK1) and ERK1/ERK2 and induces apoptosis.
E2252 SU3327 SU3327 is a potent, selective and substrate-competitive c-Jun N-terminal kinase (JNK) inhibitor with an IC50 of 0.7 μM.
E1656 AS601245 AS601245 is an orally active, selective, ATP-competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50 of 150, 220, and 70 nM for three JNK human isoforms hJNK1, hJNK2, and hJNK3, respectively.
E0072 Indirubin-3′-oxime Indirubin-3′-oxime (IDR3O, I3O) is an indirubin analogue that shows favorable inhibitory activity targeting GSK-3β and CDKs. Indirubin-3′-oxime also inhibits JNKs with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM for JNK1, JNK2, and JNK3, respectively. Indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity.
E1955New TNG348 TNG348 is an orally bioavailable allosteric inhibitor targeting the ubiquitin-specific protease USP1. It selectively and potently blocks USP1 activity, preventing deubiquitination of proliferative PCNA and FANCD2, which disrupts DNA repair mechanisms. TNG348 demonstrates inhibitory effects against BRCA1/2-mutated and homologous recombination-deficient (HRD) breast and ovarian cancers .
S0844 NDMC101 NDMC101 inhibits osteoclastogenesis which also ameliorates paw swelling and inflammatory bone destruction, associating with the inhibition of such transcription factors as NF-κB and NFATc1 as well as multiple protein kinases, including p38, ERK, and JNK.
S9075 Mulberroside A Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. Mulberroside A decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38.
E2682 RPI-1 RPI-1 inhibits proliferation of human papillary thyroid carcinoma cell line TPC-1 by inducing accumulation of cells at the G2 cell cycle phase, abolishes Ret/Ptc1 tyrosine phosphorylation along with its binding to Shc and phospholipase Cg, also abolishes the activation of JNK2 and AKT.
S4460 IMM-H007 IMM-H007, an adenosine derivative, is an activator of AMP-Activated Protein Kinase (AMPK). IMM-H007 is a potential drug for treating cardiac dysfunction. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 (ATP binding cassette subfamily a member 1) degradation and facilitates its cell-surface localization in macrophages, thereby promotes cholesterol efflux.
S6347 5'-N-Ethylcarboxamidoadenosine (NECA) 5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
S6711 IQ-1S IQ-1S is a JNK3 inhibitor with Kd values of 87, 360 and 390 nM for JNK3, JNK2 and JNK1, respectively.
S1460 SP600125 SP600125(Nsc75890)は、JNK1、JNK2、JNK3に対する広範なJNK阻害剤であり、細胞フリーアッセイでのIC50はそれぞれ40nM、40nM、90nMです。MKK4に対して10倍、MKK3、MKK6、PKB、PKCαに対して25倍、ERK2、p38、Chk1、EGFRなどに対して100倍高い選択性を示します。SP600125は、Aurora kinase AFLT3TRKAを含むserine/threonine kinasesの広範な阻害剤でもあり、IC50はそれぞれ60nM、90nM、70nMです。SP600125はautophagyを阻害し、apoptosisを活性化します。
Nat Commun, 2025, 16(1):7156
Adv Sci (Weinh), 2025, 12(28):e2502634
Adv Sci (Weinh), 2025, 12(36):e00028
SP600125-S1460W01210140905.gif
S1574 Doramapimod (BIRB 796) Doramapimod (BIRB 796) は、細胞を含まないアッセイでp38α/β/γ/δに対して38 nM、65 nM、200 nM、520 nMのIC50を持つpan-p38 MAPK阻害剤であり、THP-1細胞では0.1 nMのKdでp38αに結合し、JNK2と比較して330倍高い選択性を示します。c-RAF、Fyn、Lckに対しては弱い阻害作用を示し、ERK-1、SYK、IKK2に対しては有意な阻害作用を示しません。
Nat Cancer, 2025, 6(2):259-277
Nat Commun, 2025, 16(1):3319
Nat Commun, 2025, 16(1):1834
BIRB796-S1574W0220141114.gif
S4901 JNK-IN-8 JNK-IN-8 (JNK Inhibitor XVI) は、JNK1、JNK2、JNK3に対する初の不可逆的JNK阻害剤であり、IC50はそれぞれ4.7 nM、18.7 nM、1 nMです。A375細胞株において、MNK2、Fmsに対して10倍以上の選択性を示し、c-Kit、Met、PDGFRβに対しては阻害作用を示しません。
Cancer Cell, 2025, S1535-6108(25)00271-5
Cell Res, 2025, 10.1038/s41422-025-01085-9
Nat Commun, 2025, 16(1):4884
JNK-IN-8-S4901Z0120140901.gif
S1396 Resveratrol (trans-Resveratrol) Resveratrolは、シクロオキシゲナーゼ(例:COX、IC50=1.1 μM)、リポキシゲナーゼ(LOX、IC50=2.7 μM)、キナーゼ、Sirtuin、その他のタンパク質を含む幅広い標的を持っています。抗がん作用、抗炎症作用、血糖降下作用、その他心血管に良い効果があります。Resveratrolはmitophagy/autophagyおよびオートファジー依存性apoptosisを誘導します。
Aging Cell, 2025, e70075
Biomed Pharmacother, 2025, 190:118393
Breast Cancer Res, 2025, 27(1):186
Resveratrol-S139601W0120130129.gif
S7508 JNK Inhibitor IX JNK Inhibitor IX (TCS JNK 5a) は、JNK2 および JNK3 に対する pIC50 がそれぞれ 6.5 および 6.7 の、選択的かつ強力な JNK 阻害剤です。
Res Sq, 2025, rs.3.rs-6150649
Sci Adv, 2024, 10(50):eadq4274
Cell Mol Immunol, 2023, 20(8):908-923
JNK-Inhibitor-IX-S750801Z0420161125.gif
S8490 Tanzisertib Hydrochloride (CC-930) Tanzisertib HCl(CC-930, JNK-930, JNKI-1) is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively.
Nature, 2025, 644(8076):516-526
J Neuroinflammation, 2025, 22(1):32
Cancer Cell, 2024, 42(4):535-551.e8
S7794 JNK Inhibitor VIII JNK Inhibitor VIII (TCS JNK 6o) is an inhibitor of c-Jun N-terminal kinases with IC50 of 45 nM and 160 nM for JNK-1 and JNK-2, respectively. JNK Inhibitor VIII (TCS JNK 6o) inihibits JNK-1, JNK-2, and JNK-3 with Ki of 2 nM, 4 nM and 52 nM, respectively.
Cell, 2024, 187(14):3652-3670.e40
Cell Death Discov, 2022, 8(1):113
Molecules, 2021, 26(8)2141
S3901 Astragaloside IV Astragaloside IV (AST-IV, AS-IV) is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. It has various effect on the cardiovascular, immune, digestive, and nervous systems. AS-IV suppresses activation of p-Akt, p-mTOR, p-NF-κB and p-Erk1/2.
Cell Transplant, 2023, 32:9636897231198167
Cell Cycle, 2022, 1-14
Naunyn Schmiedebergs Arch Pharmacol, 2020, 10.1007/s00210-020-02022-w
S3292 (3R,8S)-Falcarindiol Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules.
Antioxidants (Basel), 2024, 13(12)1533
Front Cell Infect Microbiol, 2023, 13:1128000
Front Pharmacol, 2021, 12:656697
S8867 Bentamapimod (AS602801) Bentamapimod (AS602801) is a novel, orally active JNK inhibitor with IC50 values of 80 nM, 90 nM and 230 nM for JNK1, JNK2 and JNK3 respectively.
Front Oncol, 2022, 12:1006131
Nat Biomed Eng, 2018, 2(8):578-588
S8201 BI-78D3 BI-78D3 is a competitive JNK inhibitor with IC50 of 280nM that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K.
Neoplasia, 2021, 23(7):718-730
Cell Discov, 2019, 5:2
S0781 IQ 3 IQ 3 is a specific c-Jun N-terminal kinase (JNK) inhibitor with Kd of 66 nM, 240 nM and 290 nM for JNK3, JNK1 and JNK2, respectively. IQ 3 inhibits LPS-induced NF-κB/AP1 transcriptional activity in THP1-Blue cells with IC50 of 1.4 μM. IQ 3 also inhibits TNF-α and IL-6 production in vitro.
Int J Biol Sci, 2024, 20(6):2323-2338
E1391 SP 600125, negative control SP 600125, negative control (JNK inhibitor II, negative control) is a methylated analog of SP 600125 and inhibits JNK2 and JNK3 with IC50 of 18 µM and 24 µM, respectively.
Cell Death Dis, 2023, 14(8):537
S6730 CC-401 Hydrochloride CC-401 is a potent inhibitor of JNK with at least 40-fold selectivity against other related kinases.
Insect Biochem Mol Biol, 2016, 73:55-61
S3811 Ginsenoside Re Ginsenoside Re (Ginsenoside B2, Panaxoside Re, Sanchinoside Re, Chikusetsusaponin Ivc), an extract from Panax notoginseng, is a major ginsenoside in ginseng and belongs to 20(S)-protopanaxatriol group. It has diverse in vitro and in vivo effects, including vasorelaxant, antioxidant, antihyperlipidemic, and angiogenic actions. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.
J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S1321 Urolithin B Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα. Urolithin B suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass.
PLoS Pathog, 2025, 21(8):e1013401
S6740 DB07268 DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM and exhibits at least 70- to 90-fold greater potency against JNK1 than CHK1, CK2, and PLK.
E2653 JNK-IN-7 JNK-IN-7 is a strong  JNK inhibitor with IC50 of 1.5, 2 and 0.7 nM for JNK1, JNK2 and JNK3, which inhibits phosphorylation of c-Jun, direct substrate of JNK kinase.
S3242 Loureirin B Loureirin B (LB, LrB), a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of PAI-1 with IC50 of 26.10 μM. Loureirin B downregulates p-ERK and p-JNK in TGF-β1-stimulated fibroblasts. Loureirin B promotes insulin secretion mainly through increasing Pdx-1, MafA, intracellular ATP level, inhibiting the KATP current, influx of Ca2+ to the intracellular.
S0949 Cucurbitacin IIb Cucurbitacin IIb (CuIIb, Dihydrocucurbitacin F, 25-deacetyl hemslecin A) inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB, blocks nuclear translocation of NF-κB and decreases mRNA levels of IκBα and TNF-α. Cucurbitacin IIb exhibits anti-inflammatory activity and induces apoptosis. Cucurbitacin IIb is isolated from Hemsleya amabilis.
S4884 Trans-Zeatin Trans-Zeatina ((E)-Zeatin) is the member of the plant growth hormone family known as cytokinins, which regulate cell division, development, and nutrient processing. Trans-Zeatin inhibits UVB-induced MMP-1 expression, c-Jun activation and phosphorylation of ERK, JNK and p38 MAP kinases (MAPKs) dose-dependently.
S9614 CC-90001 CC-90001 is an orally administered inhibitor of c-Jun N-terminal kinase (JNK) with bias for JNK1 over JNK2. It exhibits antifibrotic efficacy and can be used for the research of idiopathic pulmonary fibrosis.
E2252 SU3327 SU3327 is a potent, selective and substrate-competitive c-Jun N-terminal kinase (JNK) inhibitor with an IC50 of 0.7 μM.
E1656 AS601245 AS601245 is an orally active, selective, ATP-competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50 of 150, 220, and 70 nM for three JNK human isoforms hJNK1, hJNK2, and hJNK3, respectively.
E0072 Indirubin-3′-oxime Indirubin-3′-oxime (IDR3O, I3O) is an indirubin analogue that shows favorable inhibitory activity targeting GSK-3β and CDKs. Indirubin-3′-oxime also inhibits JNKs with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM for JNK1, JNK2, and JNK3, respectively. Indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity.
E1955New TNG348 TNG348 is an orally bioavailable allosteric inhibitor targeting the ubiquitin-specific protease USP1. It selectively and potently blocks USP1 activity, preventing deubiquitination of proliferative PCNA and FANCD2, which disrupts DNA repair mechanisms. TNG348 demonstrates inhibitory effects against BRCA1/2-mutated and homologous recombination-deficient (HRD) breast and ovarian cancers .
S9075 Mulberroside A Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. Mulberroside A decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38.
E2682 RPI-1 RPI-1 inhibits proliferation of human papillary thyroid carcinoma cell line TPC-1 by inducing accumulation of cells at the G2 cell cycle phase, abolishes Ret/Ptc1 tyrosine phosphorylation along with its binding to Shc and phospholipase Cg, also abolishes the activation of JNK2 and AKT.
S4460 IMM-H007 IMM-H007, an adenosine derivative, is an activator of AMP-Activated Protein Kinase (AMPK). IMM-H007 is a potential drug for treating cardiac dysfunction. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 (ATP binding cassette subfamily a member 1) degradation and facilitates its cell-surface localization in macrophages, thereby promotes cholesterol efflux.
S6347 5'-N-Ethylcarboxamidoadenosine (NECA) 5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
S6711 IQ-1S IQ-1S is a JNK3 inhibitor with Kd values of 87, 360 and 390 nM for JNK3, JNK2 and JNK1, respectively.
S1950 Metformin Hydrochloride Metformin Hydrochloride(1,1-ジメチルビグアナイドHCl)は、主に肝臓によるグルコース産生(肝糖新生)を抑制することにより、肝細胞の高血糖を低下させます。Metformin Hydrochlorideは単核細胞のmitophagyを促進します。Metformin Hydrochlorideは、JNK/p38 MAPK経路とGADD153を活性化することにより、肺癌細胞のapoptosisを誘導します。
Cell Biosci, 2025, 15(1):156
mBio, 2025, e0063425
Placenta, 2025, 165:50-61
Metformin-S195007W0220150831.gif
S7409 Anisomycin (Flagecidin) Anisomycin (Flagecidin, Wuningmeisu C) is a bacterial antibiotic isolated from Streptomyces griseolus, which inhibits protein synthesis, and also act as a JNK activator. Anisomycin upregulates autophagy and increases apoptosis.
J Exp Med, 2025, 222(6)e20240272
Cell Rep Med, 2025, 6(2):101927
Theranostics, 2025, 15(10):4398-4415
Anisomycin-S740901W0220170720.gif
S5958 Metformin (1,1-Dimethylbiguanide) Metformin (1,1-Dimethylbiguanide), a widely used drug for treatment of type 2 diabetes, activates AMP-activated protein kinase (AMPK) in hepatocytes. Metformin promotes mitophagy in mononuclear cells. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153.
Signal Transduct Target Ther, 2025, 10(1):271
Theranostics, 2025, 15(17):9029-9046
Int J Biol Sci, 2025, 21(9):4231-4251
S2271 Berberine chloride Berberine chlorideは、イソキノリンアルカロイド群の第四級アンモニウム塩です。Berberine chlorideは、caspase 3caspase 8を活性化し、poly ADP-ribose polymerase (PARP)の切断とcytochrome cの放出を促進します。Berberine chlorideは、c-IAP1Bcl-2、およびBcl-XLの発現を減少させます。Berberine chlorideは、JNKp38 MAPKの持続的なリン酸化およびROSの生成を伴うapoptosisを誘導します。Berberine chlorideは、デュアルtopoisomerase IおよびII阻害剤です。Berberine chlorideは、潜在的なautophagyモジュレーターでもあります。
J Cardiovasc Dev Dis, 2025, 12(7)278
Adv Healthc Mater, 2023, e2300591.
Transl Oncol, 2023, 35:101712
S9114 Polyphyllin I Polyphyllin I, a small molecular monomer extracted from Rhizoma of Paris polyphyllin, is used in the treatment of infectious disease and cancer. Polyphyllin I inhibits proliferation and induces apoptotic cell death in U251 cells. Polyphyllin I is an activator of the JNK signaling pathway with a potential anti-glioma effect.
Discov Oncol, 2025, 16(1):941
Mol Med, 2024, 30(1):59
Oxid Med Cell Longev, 2022, 2022:4031008
S7637 DTP3 DTP3 is a selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor and is able to restore MKK7/JNK activation. DTP3 inhibits cancer-selective NF-κB survival pathway.
Life Sci Alliance, 2024, 7(8)e202302555
MedComm (2020), 2023, 4(3):e269
S3940 3'-Hydroxypterostilbene 3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies.
Int J Mol Sci, 2024, 25(18)9990
S4643 KB-R7943 mesylate KB-R7943 mesylate is a widely used inhibitor of the reverse Na+/Ca2+ exchanger (NCX(rev)) with IC50 of 5.7 μM. KB-R7943 mesylate promotes prostate cancer cell death by activating the JNK pathway and blocking autophagic flux.
E8271New Sanguinarine citrate Sanguinarine (gluconate) is a benzophenanthridine alkaloid derived from the root of Sanguinaria canadensis. It activates reactive oxygen species (ROS), c-Jun N-terminal kinase (JNK), and nuclear factor-kappaB (NF-κB) signaling pathways to induce apoptosis in head and neck tumor cells and animal models. It also exhibits potent anti-bacterial and anti-inflammatory activities.
S9698 Ezatiostat Ezatiostat, a tripeptide analog of glutathione, is a peptidomimetic inhibitor of Glutathione S-transferase P1-1 (GSTP1-1). Ezatiostat activates c-Jun NH2 terminal kinase (JNK1) and ERK1/ERK2 and induces apoptosis.
E8271New Sanguinarine citrate Sanguinarine (gluconate) is a benzophenanthridine alkaloid derived from the root of Sanguinaria canadensis. It activates reactive oxygen species (ROS), c-Jun N-terminal kinase (JNK), and nuclear factor-kappaB (NF-κB) signaling pathways to induce apoptosis in head and neck tumor cells and animal models. It also exhibits potent anti-bacterial and anti-inflammatory activities.
E1955New TNG348 TNG348 is an orally bioavailable allosteric inhibitor targeting the ubiquitin-specific protease USP1. It selectively and potently blocks USP1 activity, preventing deubiquitination of proliferative PCNA and FANCD2, which disrupts DNA repair mechanisms. TNG348 demonstrates inhibitory effects against BRCA1/2-mutated and homologous recombination-deficient (HRD) breast and ovarian cancers .

JNKシグナル伝達経路